Accurate mass measurements by Fourier transform mass spectrometry in the study of advanced glycation end products/peptides

Journal of Mass Spectrometry

Volumn 38, Issue 2, 2003, Pages 196-205

  Marotta, Ester ^a   Lapolla, Annunziata ^b   Fedele, Domenico ^b   Senesi, Antonella ^b   Reitano, Rachele ^b   Witt, Matthias ^c   Seraglia, Roberta ^a   Traldi, Pietro ^a  

^a CNR   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c BRUKER DALTONIK GMBH   (Germany)

Author keywords

Fourier transform mass spectrometry; Liquid chromatography electrospray ionization mass spectrometry; Non enzymatic glycation

Indexed keywords

CROSSLINKING; DESORPTION; FLUORESCENCE; FOURIER TRANSFORMS; IONIZATION; LASER APPLICATIONS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PROTEINS;

MAILLARD REACTIONS;

SUGARS;

ADVANCED GLYCATION END PRODUCT; HUMAN SERUM ALBUMIN; SUGAR;

ACCURACY; ARTICLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; FLUORESCENCE SPECTROSCOPY; FOURIER TRANSFORMATION; GLYCATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEASUREMENT; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; PROTEIN STRUCTURE; SEQUENCE ANALYSIS; TANDEM MASS SPECTROMETRY; ULTRAVIOLET SPECTROSCOPY;

AMINO ACID SEQUENCE; CHROMATOGRAPHY, LIQUID; GLUCOSE; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PEPTIDE MAPPING; REPRODUCIBILITY OF RESULTS; SERUM ALBUMIN; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TRYPSIN;

EID: 0037295407     PISSN: 10765174     EISSN: None     Source Type: Journal    
DOI: 10.1002/jms.431     Document Type: Article

References (32)

1. Maillard LC. Action des acides aminés sur le sucres: formation des mélanoidines per voie méthodique. C.R. Acad. Sci. 1912; 154: 138.
2. Lyons TJ, Jenkins A. Glycation, oxidation and lipooxidation in the development of the complications of diabetes: a carbonyl stress hypothesis. I. Diab. Rev. 1997; 5: 365.
3. Thornalley PJ. The clinical significance of glycation. Clin. Lab. 1999; 45: 263.
4. Chappey O, Dosquet C, Wautier MP, Wautier JL. Advanced glycation end products, oxidant stress and vascular lesions. Eur. J Clin. Invest. 1997; 27: 97.
5. Makita Z, Radoff S, Raifield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H. Advanced glycosylation end products in patients with diabetic nephropathy. N. Engl. J Med. 1991; 325: 836.
6. Gugliucci A, Bendayan M. Renal fate of circulating advanced glycated end-products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996; 39: 149.
7. Horiuchi S, Higashi T, Ikeda K, Saishoji T, Jinnouchi Y, Sano H, Shibayama R, Sakamoto T, Araki N. Advanced glycation end products and their recognition by macrophage and macrophage-derived cells. Diabetes 1996; 45: 73.
8. Dean RT. Lysosomal enzymes as agents of turnover of soluble cytoplasmatic proteins. Eur. J. Biochem. 1975; 58: 9.
9. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirkstein M, Vlassara H. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J. Exp. Med. 1991; 174: 931.
10. Deppisch R, Nawroth P. Toxicity of uraemia: does it come of AGE? Nephrol. Diel. Transplant. 1994; 9: 1.
11. Korbert SM, Makita Z, Firanek CA, Vlassara H. Advanced glycosylation end products in continuous ambulatory peritoneal dialysis patients. J. Kidney Dis. 1993; 22: 588.
12. Bucala R, Makita Z, Vaga G, Grundy S, Koshinsky T, Cerami A, Vlassara H. Modification of low density lipoprotein by advanced glycation endproducts contributes to the dyslipidemia of diabetes and renal insufficiency. Proc. Natl. Acad. Sci. USA 1994; 91: 9441.
13. Gugliucci A, Menini T. Circulating advanced glycation peptides in streptozotocin-induced diabetic rats: evidence for preferential modification of IgG light chains. Life Sci. 1998; 62: 2141.
14. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbert SM, Barth RH, Winston JA, Fuh H, Manogue KR, Cerami A, Vlassara H. Reactive glycosylation end products in diabetic uraemia and treatment of renal failure. Lancet 1994; 343: 1519.
15. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopulos D, Diamandis EP. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int. 1999; 46: 216.
16. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation end products. J Biol. Chem. 1992; 267: 5133.
17. Lapolla A, Fedele D, Senesi A, Martano L, Aricò NC, Reitano R, Favretto D, Seraglia R, Astner H, Traldi P. Advenced glycation end-products/peptides: a preliminary investigation by LC and LC/MS. Farmaco submitted for publication.
18. Lapolla A, Gerhardinger C, Baldo L, Fedele D, Keane A, Seraglia R, Catinella S, Traldi P. A study on in vivo glycation processes by matrix assisted laser desorption ionization mass spectrometry. Biochim. Biophys. Acta 1993; 1225: 33.
19. Lapolla A, Fedele D, Aronica R, Curcuruto O, Hamdam M, Catinella S, Seraglia R, Traldi P. Investigation of the reaction between N-α-acetyl-L-lysin amide and glucose by electrospray mass spectrometry. Rapid Commun. Mass Spectrom. 1995; 9: 69.
20. Lapolla A, Fedele D, Seraglia R, Catinella S, Baldo L, Aronica R, Traldi P. A new effective method for the evaluation of glycated intact plasma proteins in diabetic subjects. Diabetologia 1995; 38: 1076.
21. Lapolla A, Fedele D, Aronica R, Baldo L, D'Alpaos M, Seraglia R, Traldi P. The in vivo glycation of lysozyme and the influence of buffer concentration investigated by mass spectrometry. Rapid Commun. Mass Spectrom. 1996; 10: 1512.
22. Lapolla A, Fedele D, Aronica R, Garbeglio M, D'Alpaos M, Seraglia R, Traldi P. Evaluation of IgG glycation levels by matrix assisted laser desorption/ionisation mass spectrometry. Rapid Commun. Mass Spectrom. 1997; 11: 1342.
23. Lapolla A, Fedele D, Plebani M, Aronica R, Garbeglio M, Seraglia R, D'Alpaos M, Traldi P. Evaluation of glycated globins by matrix-assisted laser desorption/ionisation mass spectrometry. Clin. Chem. 1999; 2: 288.
24. Lapolla A, Gerhardinger C, Baldo L, Crepaldi G, Fedele D, Porter CJ, Seraglia R, Favretto D, Traldi P. Investigation of products arising from enzymatic digestion of advanced glycated albumin by HPLC/MS. Rapid Commun. Mass Spectrom. 1991; 5: 624.
25. Bergquist J, Palmblad M, Wetterhall M, Hakansson P, Markidas KE. Alkyl isocyanates as active-site-specific reagents for serine proteases. Reaction properties. Mass Spectrom. Rev. 2002; 21: 215.
26. Brown W, Wold F. Peptide mapping of proteins in human body fluids using electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. Biochemistry 1973; 12: 828.
27. Jeno P, Mini T, Hintermann E, Horst M. Internal sequences from proteins digested in polyacrylamide gels. Anal. Biochem. 1995; 224: 451.
28. Lewis KJ, Wei J, Siuzdak G. In Encyclopedia of Analytical Chemistry, Meyers RA (ed.). Wiley: Chichester, 2000; 5880-5894.
29. Dienes T, Pastor SJ, Schürch, Scott JR, Yao J, Cui S, Wilkins CL. Fourier transform mass spectrometry - advancing years (1992-mid. 1996). Mass Spectrom. Rev. 1996; 15: 163.
30. Lapolla A, Fedele D, Martano L, Aricò NC, Garbeglio M, Traldi P, Seraglia R, Favretto D. Advanced glycation end products: a highly complex set of biologically relevant compounds detected by mass spectrometry. J. Mass Spectrom. 2001; 36: 370.
31. Schidner SL, Kohn RR. Effects of age and diabetes mellitus on the solubility of collagen from human skin, tracheal cartilage and dura mater. Exp. Gerontol. 1982; 17: 185.
32. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest. 1991; 70: 138.